MyoKardia, Inc.
(NASDAQ : MYOK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
PTLAPortola Pharmaceuticals, Inc. 0.56%17.956.5%$165.07m
HZNPHorizon Therapeutics Plc 4.06%50.736.5%$146.36m
CTLTCatalent, Inc. 0.81%77.522.3%$138.66m
MYOKMyoKardia, Inc. 2.14%102.291.8%$130.35m
BHCBausch Health Cos., Inc. -0.75%18.440.0%$119.26m
VRXValeant Pharmaceuticals International, Inc. -0.75%18.4414.1%$108.50m
UTHRUnited Therapeutics Corp. 2.57%117.9514.3%$75.18m
JAZZJazz Pharmaceuticals Plc 0.45%119.322.4%$60.64m
ICPTIntercept Pharmaceuticals, Inc. -0.66%72.2616.8%$59.67m
AMRNAmarin Corp. Plc 0.44%6.861.6%$57.99m
GWPHGW Pharmaceuticals Plc -2.16%122.756.2%$55.98m
ARGXargenx SE 3.60%219.300.0%$52.90m
AXSMAxsome Therapeutics, Inc. 0.60%76.981.9%$50.67m
PRGOPerrigo Co. Plc -0.42%54.806.8%$45.78m
ICLRICON plc 1.72%168.454.3%$44.44m

Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.